Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 10, 2013, Pages 1844-1852

  Koga, Yoshikatsu ^a   Yamazaki, Nobuyoshi ^a   Yamamoto, Yoshiyuki ^a   Yamamoto, Seiichiro ^b   Saito, Norio ^a   Kakugawa, Yasuo ^c   Otake, Yosuke ^c   Matsumoto, Minori ^c   Matsumura, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b National Cancer Center Hospital   (United States)

^c NATIONAL CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 106A; MICRORNA 132; MICRORNA 142 3P; MICRORNA 15B; MICRORNA 16; MICRORNA 19A; MICRORNA 19B; MICRORNA 20B; MICRORNA 223; MICRORNA 342 3P; MICRORNA 451; MICRORNA 92A; MICRORNA 93; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FECAL MICRORNA TEST; FECES ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; OCCULT BLOOD; TUMOR MARKERS, BIOLOGICAL;

EID: 84886424225     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0512     Document Type: Article

References (29)

1. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7.
2. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002;50: 840-4.
3. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002;50:29-32.
4. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J. Immunochemical faecal occult blood tests are superior to guaiacbased tests for the detection of colorectal neoplasms. Eur J Cancer 2008;44:2254-8.
5. Parra-Blanco A, Gimeno-Garcia AZ, Quintero E, Nicolas D, Moreno SG, Jimenez A, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 2010;45:703-12.
6. Lieberman DA, Weiss DGVeterans Affairs Cooperative Study G. Onetime screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001;345: 555-60.
7. Sung JJ, Chan FK, Leung WK,WuJC, Lau JY, Ching J, et al. Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology 2003; 124:608-14.
8. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross MEColorectal Cancer Study G. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14.
9. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129:422-8.
10. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009; 59:27-41.
11. Matsushita H, Matsumura Y, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al. A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology 2005;129:1918-27.
12. Onouchi S, Matsushita H, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al. New method for colorectal cancer diagnosis based on SSCP analysis of DNA from exfoliated colonocytes in naturally evacuated feces. Anticancer Res 2008;28:145-50.
13. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008;149:441-50, W81.
14. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 2004;127: 422-7.
15. Leung WK, To KF, Man EP, ChanMW,Hui AJ,Ng SS, et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol 2007;102:1070-6.
16. Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N, et al. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7mRNAassays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2009;18:1888-93.
17. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58: 1375-81.
18. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
19. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova- Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105: 10513-8.
20. Bovell L, Shanmugam C, Katkoori VR, Zhang B, Vogtmann E, Grizzle WE, et al. miRNAs are stable in colorectal cancer archival tissue blocks. Front Biosci (Elite edition) 2012;4:1937-40.
21. Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al. Exosome can prevent RNase from degrading microRNA in feces. J Gastrointest Oncol 2011;2:215-22.
22. Yamazaki N, Koga Y, Yamamoto S, Kakugawa Y, Otake Y, Hayashi R, et al. Application of the fecal microRNA test to the residuum from the fecal occult blood test. Jpn J Clin Oncol 2013;43:726-33.
23. Murata S, Koga Y, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al. Application of miRNA expression analysis on exfoliated colonocytes for colorectal cancer diagnosis. Gastrointest Cancer 2012; 2:11-8.
24. Koga Y, Yasunaga M, Takahashi A, Kuroda J, Moriya Y, Akasu T, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer PrevRes 2010;3:1435-42.
25. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010;19:1766-74.
26. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, Sileri P, Cretella M, Pallone F, et al. Differential expression of miR-144 as a novel fecalbased diagnostic marker for colorectal cancer. J Gastroenterol 2011; 46:1391-402.
27. Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012;61:739-45.
28. Calistri D, Rengucci C, Casadei Gardini A, Frassineti GL, Scarpi E, Zoli W, et al. Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals. Cancer Epidemiol Biomarkers Prev 2010;19:2647-54.
29. Feng B, Dong TT, Wang LL, Zhou HM, Zhao HC, Dong F, et al. Colorectal cancer migration and invasion initiated by microRNA- 106a. PLoS One 2012;7:e43452.